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One of the strategies to maintain optimal gut health in animal production in the absence of 
antibiotic growth promoters is to support the active immunity of the animal. Immunity at the level of 
the digestive system is concentrated in the mucosal immune system of the gut associated lymphoid 
tissue (GALT). Therefore, the GALT is the obvious target if we want to increase intestinal immunity. 
M cells and dendritic cells sample the intestinal contents and bring pathogens in close contact with 
macrophages, B and T cells in specialized regions in the intestinal epithelium like e.g. the Peyer’s 
patches (inductive site). Macrophages destroy the pathogen and stimulate the B and T cells to 
launch an immune response that is specific to this pathogen. Depending on the pathogen and the 
co-stimulatory signals this response can be the activation of cellular (cytoxic T lymphocytes (CTL)) or 
humoral (antibodies) immunity. Antibodies (IgA) are secreted at the effector site and transported 
through the epithelial cells to neutralize the pathogens already in the intestinal lumen. Macrophages 
thus act at the first line and stimulate a whole cascade of events leading to final antibody 
production. 
The intense contact between intestinal contents and immune cells at the mucosa offers 
opportunities to modulate intestinal immunity via the feed. While immunostimulating activities are 
claimed on many feed additives like phytoproducts, organic acids, chelates, pre- and probiotics and 
many others these additives mostly have only bacteriostatic effects or indirect effects on the 
immune system. On the contrary, it has been widely demonstrated that β-glucans have a direct 
immunostimulating effect. More specifically they bind to a receptor on macrophages and increase 
their activity towards stimulation of B and T cells. As a consequence, increased antibody titers after 
vaccination and better protection after challenges with a pathogen have been observed when β-
glucans were incorporated in the feed. However, not all β-glucans are equally effective and their 
interaction with the receptor on the macrophage depends on their primary and secondary structure 
(degree of polymerization (DP) and degree of substitution (DS)). 
Since immunization and challenge trials are laborious, time consuming and therefore very costly we 
propose to develop a model system based on in vitro assays that can be used to evaluate the 
immunomodulating property of feed additives. Β-glucans with different purity, DP and DS can thus 
be compared. Most if not all sources of β-glucans that are used in feed are impure or semi-purified 
compounds that contain a variety of oligosaccharides including mannan-oligosaccharides or MOS. 
These molecules can interfere with the attachment of pathogenic bacteria (e.g. enterotoxic 
Escherichia coli or ETEC) to the intestinal epithelial thus reducing their colonization. Next to 
immunomodulation this is another aspect of the possible positive effect of these compounds on gut 
health. In our lab, interference of attachment of bacteria to the intestinal epithelium can also be 
quantified in vitro. 
As outlined above, once a pathogen is sampled out of the intestinal contents a local immune 
response in the intestinal mucosa is generated in different steps. At first macrophages and other 
phagocytic cells (like dendritic cells ; non-specific immunity) take up the pathogen. They destroy the 
pathogen with enzymes and O-radicals and process it for presentation to local T cells. Phagocytic 
cells also secrete pro-inflammatory cytokines that stimulate the activity and proliferation of those T 
and B cells that are most fit to attack the type of pathogen that was presented by the phagocytic cell 
(specific immunity). Finally the B cells will produce antibodies (IgA) that can be secreted in the 
intestinal lumen to neutralize the pathogens. 
The benefits and values of these assays are that the activity of all the samples within each test will 
be comparable. Also, the results will give an activity profile of each sample, indicating at what level 
the immunological response is most probably modulated when the sample is included in the feed. 
Furthermore, the capacity of a sample to interfere with attachment of E coli is a measure of 
protection against attachment and colonization of the intestinal epithelium in vivo. And finally, 
validation of the results of the in vitro screening towards gut health and protection against 
pathogenic challenges will have to be performed by in vivo tests 
 
